Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
about
Haploidentical Stem Cell Transplantation in Adult Haematological MalignanciesNonmyeloablative allogeneic hematopoietic cell transplantationHow do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic MalignanciesChoice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published LiteratureHaploidentical Transplantation in Children with Acute Leukemia: The Unresolved IssuesHLA Haplotype Mismatch Transplants and Posttransplant CyclophosphamideMyeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant CyclophosphamideComparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched TransplantationAn update of current treatments for adult acute myeloid leukemiaModern approaches to HLA-haploidentical blood or marrow transplantationNovel therapeutic options in Acute Myeloid LeukemiaThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseImmunity to Infections after Haploidentical Hematopoietic Stem Cell TransplantationHaploidentical transplantation of hematopoietic stem cells.Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Immunotherapy in hematologic malignancies: past, present, and future.Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT.Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantationThe effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.Might haplo "be the (better) match"?Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters.The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide.Overview of the progress on haploidentical hematopoietic transplantation.A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplantErythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC.Recent developments in HLA-haploidentical transplantations.The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy.Frontline treatment of acute myeloid leukemia in adults.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.
P2860
Q26745527-D14B3DC8-BA5B-4999-8643-4A4482901496Q26748780-7097D890-2E5F-4312-A08A-6C15998F9B9EQ26748867-AA2235EC-2A83-4006-86FC-4CF4F63CE5C7Q26749120-B75DE45B-7311-4E5B-BE92-0E60A6CCCDE8Q26749454-34CB7A18-D4B8-4410-B652-F3D4F4E4C1F2Q26750671-9100D893-9E6E-40F0-A251-7D957C60B1F2Q26752908-389EDC10-6BF2-451E-9C1E-8B2D549E5E79Q26767438-0A3D83FB-94F8-44FB-8915-6F4C8C312859Q26771749-040645BB-D0D8-438E-B13E-2E0CEAD93D51Q26776396-59CDD502-96A8-4240-B670-6F09892946A0Q26797506-8A929FDF-54EB-47C5-A498-E29E1F73A961Q28069889-3BABBCCD-78EC-4ED4-B208-58885233AFEAQ28072397-FABABBAE-25E9-4CE1-A2AF-0E5F3917AC3BQ28076264-0A82F019-F13C-400B-B659-9C1765EC15EAQ28079606-67355226-F306-4539-A6C3-61FAF917092DQ30240041-16FDA618-7986-450E-AD85-F571C0F837B8Q30240140-0D41AEAB-89A0-463A-B4E1-149BCA6CF0B4Q30252339-59DA19EE-7A72-4272-BF39-E1CC0506C785Q33593865-BCB64734-D69F-48DE-8EA3-FD9DEC22AAFAQ33746730-DA814826-5FAC-4DED-8BD1-B3B4C6FB9045Q33764825-AE1492F3-FEF2-4C60-B56F-A62FA1012A80Q36463393-30895DB7-C983-4238-8ECA-36B9CB4EF8D5Q36596844-AE6FBE34-768C-497F-A5A0-193552CDBB75Q36596897-4B1D1A1A-8E36-4066-93BA-A8CBD14033EBQ36687119-5B790D33-DA5C-450E-BA87-FA1F3BD35F51Q36724916-89400395-A891-4420-81FC-8F7BCCF72003Q37029856-0456DE4B-DBD4-4337-BD90-96FC49C97123Q37076010-8FEDA166-8B49-41EA-BE51-71B43C95D46FQ37148409-FEF8B4EF-5F95-4A7A-976C-C8DFC0D5F39FQ37317804-560D39E9-85F4-45E5-99F3-5384163E1D9CQ37522577-0BB7BCDD-E14C-4C23-95B8-FCA95B9ADFF8Q37595693-E25A6EAA-79A8-474F-A511-65ED64F9D323Q37618838-F66D64CE-FE41-4AE0-808D-AA1510FE4283Q37618840-892295E8-B14C-426E-BECE-70A6CAC27119Q38628563-F9C3B0BA-02C3-4678-8F4C-EC8CC058C94EQ38641733-45C05F59-EC10-4D65-94D7-EF392ABF8193Q38728327-11A3DA9C-438D-4863-8EAF-5FB8C0A3114FQ38767583-B474DA99-8B8E-42C1-8D69-08ECD4E9AC63Q38777460-4C4E81D2-3967-4487-9408-425016249CD5Q38800455-C83CBC17-D1B3-4608-893A-28EB40609FC5
P2860
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Haploidentical transplant with ...... nt for acute myeloid leukemia.
@ast
Haploidentical transplant with ...... nt for acute myeloid leukemia.
@en
type
label
Haploidentical transplant with ...... nt for acute myeloid leukemia.
@ast
Haploidentical transplant with ...... nt for acute myeloid leukemia.
@en
prefLabel
Haploidentical transplant with ...... nt for acute myeloid leukemia.
@ast
Haploidentical transplant with ...... nt for acute myeloid leukemia.
@en
P2093
P2860
P1433
P1476
Haploidentical transplant with ...... nt for acute myeloid leukemia.
@en
P2093
Andrea A Bacigalupo
Asad Bashey
Daniel H Fowler
Daniel J Weisdorf
David L Porter
Ephraim J Fuchs
Joseph H Antin
Junfang Chen
Leo Luznik
Marcie R Riches
P2860
P304
P356
10.1182/BLOOD-2015-04-639831
P407
P577
2015-06-30T00:00:00Z